4.2 Direction of Technical Development of Blood Typing Reagents
4.2.1 Current Status of Technical Development of Blood Typing Reagents
In recent years, in vitro diagnostic (henceforth referred to as IVD) reagents have been playing an increasingly greater role in disease prevention, diagnosis, prognostic judgment, screening and test of therapeutic drug, health status evaluation, estimation of heritability and other aspects, and IVD industry has become one of China’s industries with rapid development and promising future.
It can be learned from research and analysis of domestic blood typing reagent patents that most blood typing reagents belong to optimized, improved, or supplementary products at the moment. Trend of domestic blood typing reagent patent applications can be seen from Fig. 3, number of domestic Blood typing reagent-related patent applications increased rapidly between 2014 and 2017, which reached the peak of 38 applications for the whole year of 2017. The number of patent applications dropped somewhat in 2018 and 2019, but remained above 20. Therefore, trend of blood typing reagent patent application’s basically similar to that of blood typing instruments, and China’s technical researches on blood typing reagents are currently at the stage of active development; the number of patent applications comparatively reduced in 2020 and 2021, but there were still certain number of applications. Besides, the number of patent applications in 2021 increased to a certain extent in comparison with that in 2020, so technical R&D of China’s Blood typing reagent sector is still at development stage, which is expected to experience a new round of development at the next stage (Fig. 3).

Copyright © 2026 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.